Microvascular Dysfunction in Aortic Stenosis

Aortic Stenosis Clinical Trial

— PRIMID-AS  

Official title:

Prognostic Importance of Microvascular Dysfunction in Asymptomatic Patients With Aortic Stenosis (PRIMID-AS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01658345
• Other study ID #: 87768
• Status: Completed
• Phase: N/A
• First received: July 6, 2012
• Last updated: February 20, 2015
• Start date: April 2012
• Est. completion date: October 2014

Study information

• Verified date: February 2015
• Source: University Hospitals, Leicester
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Institute for Health ResearchUnited Kingdom: Research Ethics Committee
• Study type: Observational

Clinical Trial Summary

Aortic stenosis (AS), or narrowing of the aortic valve, is the commonest condition requiring valve surgery in the developed world. It is currently not known what determines who will go on to develop symptoms. Exercise testing may be able to identify these patients better than the severity of the narrowing itself, but with some limitations.

The purpose of this study is to compare whether MRI scanning or exercise testing can better identify patients with AS who are likely to benefit from surgery.

Design: The investigators will measure blood flow to the heart muscle with MRI scanning and perform exercise testing in 170 patients with AS and follow them for up to up to 2 years. Expected outcomes: MRI scanning will more accurately identify those patients with AS who will need surgery during this period. Anticipated Health Benefits: improved selection of patients with AS who are likely to benefit from early surgery. This is likely to reduce deaths in such patients.

Description:

Surgical AVR remains the universally accepted management for symptomatic aortic stenosis (AS). However, the best management of severe aortic stenosis, in the absence of symptoms, remains one of the most controversial areas in modern Cardiology.

Exercise testing can identify asymptomatic patients with AS at increased risk, but with limited specificity. In a BHF funded project, the investigators have identified that cardiac MRI measured Myocardial Perfusion Reserve (MPR) may be a novel imaging biomarker in AS. MPR was the only independent predictor of aerobic exercise capacity (peak VO2) in patients with severe AS and was also inversely related to symptomatic status.

In this multi-centre, observational, cohort outcome study, the investigators will follow 175 patients with asymptomatic moderate to severe AS for a minimum of 12 months, and determine whether MPR is a better predictor of outcome than exercise testing, elucidate the mechanisms contributing to symptom development in AS and establish the determinants of MPR in AS. Patients will be recruited from tertiary Cardiac centres, as well as regional hospitals. Comprehensive CMR with adenosine stress to determine LV mass and function, focal and diffuse fibrosis and MPR; cardiopulmonary exercise testing (peak VO2 and exercise symptoms); rest and exercise echocardiography (AS severity, valve compliance) and NT-proBNP will be performed. The study will be run in conjunction with the Glasgow CTU. Investigations will be analysed blind to patient status and data will be entered in a validated database. Statistical analysis will be performed under the supervision of Prof. Ian Ford. The relationship between MPR and exercise testing with 1-year outcome will be analysed using logistic regression. Paired comparisons of the specificities of the two approaches on the same dataset will be carried out using McNemar's test.

The primary hypothesis is that MPR will be a better predictor of adverse outcome than exercise testing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: October 2014
• Est. primary completion date: November 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Moderate-severe aortic stenosis (2 or more of: AVA < 1.5cm2, peak PG >36mmHg or mean PG > 25mmHg).

2. Asymptomatic.

3. Age > 18 years and < 85 years.

4. Prepared to consider AVR if symptoms develop.

5. Ability to perform bicycle exercise test

Exclusion Criteria:

1. History of CABG or MI within previous 6 months.

2. Severe valvular disease other than AS.

3. Previous Valve surgery

4. Persistent Atrial Fibrillation or Flutter

5. History of Heart Failure

6. Severe Asthma.

7. Severe renal impairment eGFR < 30ml/min.

8. Planned aortic valve replacement.

9. Significant LV systolic dysfunction (EF < 40%)

10. Any absolute contraindication to CMR

11. Any absolute contraindication to Adenosine

12. Participation in an Interventional Clinical Trial at Inclusion.

13. Other medical condition that limits life expectancy or precludes AVR.

14. Pregnancy

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Aortic Stenosis
• Aortic Valve Stenosis
• Constriction, Pathologic

Locations

Country	Name	City	State
United Kingdom	University of Glasgow	Glasgow
United Kingdom	Leeds General Infirmary	Leeds	West Yorkshire
United Kingdom	Glenfield Hospital	Leicester	Leicestershire

Sponsors (1)

Lead Sponsor	Collaborator
University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J. 2005 Jul;26(13):1309-13. Epub 2005 Apr 8. — View Citation

McCann GP, Steadman CD, Ray SG, Newby DE; British Heart Valve Society. Managing the asymptomatic patient with severe aortic stenosis: randomised controlled trials of early surgery are overdue. Heart. 2011 Jul;97(14):1119-21. doi: 10.1136/hrt.2011.223800. Epub 2011 Mar 12. — View Citation

Steadman CD, Jerosch-Herold M, Grundy B, Rafelt S, Ng LL, Squire IB, Samani NJ, McCann GP. Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. JACC Cardiovasc Imaging. 2012 Feb;5(2):182-9. doi: 10.1016/j.jcmg.2011.09.022. — View Citation

Steadman CD, Ray S, Ng LL, McCann GP. Natriuretic peptides in common valvular heart disease. J Am Coll Cardiol. 2010 May 11;55(19):2034-48. doi: 10.1016/j.jacc.2010.02.021. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Typical AS Symptoms necessitating AVR.		12 months	No
Primary	Cardiovascular death.		12 months	No
Primary	Major adverse cardiovascular events (MACE)	MACE: hospitalisation with heart failure, chest pain, syncope, arrhythmia or stroke	12 months	No
Secondary	Individual components of primary composite outcome measures.	Typical symptoms requiring referral for AVR, cardiovascular death, Major adverse cardiovascular events.	Upto 2 years.	No
Secondary	Development of typical symptoms, AVR, death from any cause or MACE during the entire study period.		2 years	No